{"entity":{"id":"nct01037478","kind":"trial","name":"Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma","aka":[],"tldr":"A phase 2 trial of Resminostat in Hodgkin lymphoma, run by 4SC AG, completed.","summary":"Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT01037478 by 4SC AG, with 37 participants recorded, started 2009-12 and reaching its primary completion in 2012-01. Interventions recorded: Resminostat (4SC-201). Conditions recorded: Hodgkin's Lymphoma.\n\nLinked to the drug Resminostat because the registry names it among its interventions and Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01037478","url":"https://clinicaltrials.gov/study/NCT01037478"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["resminostat"],"companies":["4sc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01037478","phase":"2","setting":"A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma","sponsor":"4SC AG","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01037478/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"drug":[{"id":"resminostat","kind":"drug","name":"Resminostat","route":"/drugs/resminostat/"}],"company":[{"id":"4sc","kind":"company","name":"4SC","route":"/companies/4sc/"}]}}